34 results
EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...
EuroPCR 2026 – Outcomes with left atrial appendage closure vs. direct oral anticoagulants in patients with atrial fibrillation across different age groups
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a subgroup analysis of the CHAMPION-AF trial investigating stroke-prevention strategies...
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
2026 Andreas Grüntzig Ethica Award presented to Roxana Mehran
20 May 2026
Each year, the Andreas Grüntzig Ethica Award – the highest honour in the interventional cardiology community – is presented to those who have contributed in an extraordinary way to the PCR mission.
EuroIntervention Achieves Record Impact Factor of 9.5
25 Jun 2025
Toulouse, FRANCE: Clarivate, publisher of the Journal Citation Reports (JCR) has announced the new Impact Factor for EuroIntervention of 9.5, putting it in the top percentile of academic publications published today.
EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
EuroPCR 2025 – Meta-Analysis of Individual Patient Data from the PROTECTED TAVR and BHF PROTECT-TAVI Trials
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the...
2025 Andreas Grüntzig Ethica Award presented to Lars Wallentin and Stefan James on behalf of Swedish cardiovascular registry experts
20 May 2025
The Andreas Grüntzig Ethica Award is traditionally given to those who have contributed in an extraordinary way to the PCR mission, that of serving the needs of patients by sharing knowledge, experience and practice in cardiovascular interventional medicine.
EuroPCR 2025 – The place to share solutions
07 May 2025
The annual World-Leading Course in interventional cardiovascular medicine is the official meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Thousands of participants will once again be gathering to share their knowledge, skills and experience on 20-23 May 2025, at the Palais des Congrès in...
